Can Th2 priming, reduced histamine clearance, and omega-6 leukotriene bias make allergic signals easier to trigger and longer-lasting?

Allergic hyper-reactivity is driven by a highly integrated, feed-forward network where genetic priming, metabolic clearance deficits, and lipid mediator biases converge to compound inflammatory signaling.

Mechanistic synergy of allergic priming

• Th2-driven sensitization: Upstream Th2 cytokines, particularly interleukin-4 (IL-4) and thymic stromal lymphopoietin (TSLP), lower effector cell activation thresholds. IL-4 directly upregulates the high-affinity IgE receptor (FcεRI) and induces leukotriene C4 synthase (LTC4S) expression in mast cells, priming them for high-output mediator release.
• Histamine accumulation and Th2 skewing: Impaired histamine clearance from genetic or functional deficits in diamine oxidase (DAO/AOC1) or histamine N-methyltransferase (HNMT) leads to elevated tissue-level histamine. This excess histamine acts via the H2 receptor (H2R) to suppress interleukin-12 (IL-12), promoting downstream Th2 differentiation and sustaining the allergic phenotype.
• Omega-6 leukotriene feed-forward loop: Under Th2-biased conditions, elevated histamine and IL-4 synergistically upregulate the biosynthesizing enzymes and receptors for cysteinyl leukotrienes (CysLT1R and CysLT2R). This amplifies the highly potent inflammatory effects of the omega-6 arachidonic acid pathway.

Clinical implications

• Lowered trigger threshold: The convergence of these pathways means significantly smaller environmental or dietary exposures are capable of triggering robust allergic cascades.
• Prolonged and heightened response: Because histamine degradation is stalled and cysteinyl leukotriene pathways are hyper-sensitized, physiological symptoms—such as bronchoconstriction and vascular permeability—are structurally amplified and slower to resolve.

Bottom line

• Bottom line: Th2 genetic priming, reduced histamine clearance, and omega-6 leukotriene bias form a self-reinforcing physiological loop that lowers the threshold for mast cell activation, intensifies mediator release, and prolongs tissue-level inflammatory signaling.